Weesp, Netherlands

Antonius Hulkenberg


Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1992-1995

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Antonius Hulkenberg

Introduction

Antonius Hulkenberg is a notable inventor based in Weesp, Netherlands. He has made significant contributions to the field of chemistry, particularly in the development of new compounds with potential applications in medicine. With a total of 3 patents, his work reflects a commitment to advancing scientific knowledge and innovation.

Latest Patents

Hulkenberg's latest patents include the invention of 3,4-dehydropiperidine derivatives. This invention relates to a group of new 3,4-dehydropiperidine derivatives characterized by specific chemical formulas, where R1 can be a hydrogen atom or an alkyl group with 1-3 carbon atoms. Another significant patent involves di- and tetrahydroisoquinoline derivatives, which are new compounds exhibiting interesting cytostatic properties. These compounds are not only innovative but also hold promise for use as cytostatically active substances in various compositions.

Career Highlights

Antonius Hulkenberg is associated with Duphar International Research Bv, where he has been instrumental in research and development. His work has contributed to the advancement of pharmaceutical sciences, particularly in the synthesis of novel compounds that may lead to new therapeutic options.

Collaborations

Hulkenberg has collaborated with several talented individuals in his field, including Ineke Van Wijngaarden and Maurits E Vandewalle. These collaborations have fostered a productive research environment, leading to innovative discoveries and advancements.

Conclusion

Antonius Hulkenberg's contributions to the field of chemistry through his patents and collaborative efforts highlight his role as a significant inventor. His work continues to inspire advancements in pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…